Zhejiang Lingge Pharmaceutical

Lingge Pharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the development of high-quality biologics for ophthalmic and oncological conditions. The company focuses on creating biosimilars and innovative therapies that address significant unmet medical needs in the retinal disease space. Its lead program, LG001, is a ranibizumab biosimilar that has progressed into Phase 3 clinical trials for neovascular age-related macular degeneration. Supported by prominent venture capital firms, Lingge Pharmaceutical integrates research, development, and manufacturing to deliver cost-effective treatments to patients. The company's pipeline also includes biosimilars for aflibercept and other key therapeutic proteins.